5/30
07:24 am
glue
Monte Rosa Therapeutics Announces Leadership Team Promotions [Yahoo! Finance]
Neutral
Report
Monte Rosa Therapeutics Announces Leadership Team Promotions [Yahoo! Finance]
5/30
07:00 am
glue
Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference
Neutral
Report
Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference
5/30
07:00 am
glue
Monte Rosa Therapeutics Announces Leadership Team Promotions
Neutral
Report
Monte Rosa Therapeutics Announces Leadership Team Promotions
5/22
11:14 am
glue
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
Medium
Report
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
5/21
07:13 am
glue
Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease [Yahoo! Finance]
High
Report
Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease [Yahoo! Finance]
5/21
07:00 am
glue
Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease
High
Report
Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease
5/16
07:17 am
glue
Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering [Yahoo! Finance]
Medium
Report
Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering [Yahoo! Finance]
5/16
07:00 am
glue
Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering
Medium
Report
Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering
5/15
04:09 pm
glue
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
Medium
Report
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
5/15
04:01 pm
glue
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Medium
Report
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
5/9
07:06 am
glue
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
5/9
07:00 am
glue
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
Medium
Report
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
5/2
04:13 pm
glue
Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer [Yahoo! Finance]
Low
Report
Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer [Yahoo! Finance]
5/2
04:01 pm
glue
Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer
Low
Report
Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer
3/22
10:51 am
glue
Monte Rosa Therapeutics (GLUE) Is a Great Choice for 'Trend' Investors, Here's Why [Yahoo! Finance]
Low
Report
Monte Rosa Therapeutics (GLUE) Is a Great Choice for 'Trend' Investors, Here's Why [Yahoo! Finance]
3/19
12:08 pm
glue
Wall Street Analysts Predict an 117.91% Upside in Monte Rosa Therapeutics (GLUE): Here's What You Should Know [Yahoo! Finance]
Low
Report
Wall Street Analysts Predict an 117.91% Upside in Monte Rosa Therapeutics (GLUE): Here's What You Should Know [Yahoo! Finance]
3/15
07:29 am
glue
Is Monte Rosa Therapeutics (NASDAQ:GLUE) In A Good Position To Invest In Growth? [Yahoo! Finance]
Medium
Report
Is Monte Rosa Therapeutics (NASDAQ:GLUE) In A Good Position To Invest In Growth? [Yahoo! Finance]
3/14
07:18 am
glue
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
3/14
07:00 am
glue
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Medium
Report
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
3/11
08:16 am
glue
MOMA Therapeutics Appoints Jullian G. Jones, Ph.D., J.D., MBA, as Chief Business Officer [Yahoo! Finance]
Medium
Report
MOMA Therapeutics Appoints Jullian G. Jones, Ph.D., J.D., MBA, as Chief Business Officer [Yahoo! Finance]
3/11
07:35 am
glue
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1ß Pathway Inhibitor [Yahoo! Finance]
Medium
Report
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1ß Pathway Inhibitor [Yahoo! Finance]
3/11
07:00 am
glue
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1ß Pathway Inhibitor
Medium
Report
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1ß Pathway Inhibitor